18 December 2024 - NICE has published final Evidence-based recommendations on the use of ublituximab (Briumvi) for the treatment of adults with relapsing multiple sclerosis.

Ublituximab is recommended as an option for the treatment of adults with relapsing forms of multiple sclerosis, defined as active by clinical or imaging features only if:

• The multiple sclerosis is relapsing-remitting
• Neuraxpharm provides it according to the commercial arrangement

Read NICE technology appraisal guidance